Adagio Medical reports Q1 2026 net loss $7.0M, cash $12.9M; FULCRUM-VT shows 84% freedom from ICD shock

Adagio Medical Holdings, Inc.

• Net loss of $7.0M for Q1 2026 vs $7.7M in Q1 2025; no revenue; R&D expense $2.7M, SG&A $2.5M.
• Cash and equivalents of $12.9M as of March 31, 2026; up to $31M additional from milestone-based warrants.
• FULCRUM-VT pivotal trial: 84% freedom from ICD shock at 6 months, 2.4% MAE, 72% reduction in antiarrhythmic drug use.
• FDA approved IDE to expand FULCRUM-VT trial to evaluate next-generation vCLAS Ultra System.
• Successfully completed 13 cases under FDA Expanded Access in patients who failed prior ablation therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.